Phase II trial of intravenous melphalan for metastatic colorectal carcinoma - A Southwest Oncology Group study

William A. Knight; Phyllis Goodman; Sarah A. Taylor; John S. Macdonald; Charles A. Coltman; John J. Constanzi; Laurence H. Baker

doi:10.1007/BF00171991

Phase II trial of intravenous melphalan for metastatic colorectal carcinoma - A Southwest Oncology Group study

William A. Knight, Phyllis Goodman, Sarah A. Taylor, John S. Macdonald, Charles A. Coltman, John J. Constanzi, Laurence H. Baker

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting dose of 40 mg/m² was reduced to 30 mg/m² after severe myelotoxicity was encountered in the first five patients. Toxicity was primarily myeloid and was moderate to severe in most patients with one treatment related death. There were two complete and one partial response among 43 patients. Melphalan at 30 mg/m² has little activity among patients with metastatic colorectal carcinoma.

Original language	English (US)
Pages (from-to)	S87-S89
Journal	Investigational New Drugs
Volume	8
Issue number	1 Supplement
DOIs	https://doi.org/10.1007/BF00171991
State	Published - Mar 1990
Externally published	Yes

Keywords

colon cancer
melphalan

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00171991

Cite this

@article{f567d87a0ae9416d8a709b19f610caa6,

title = "Phase II trial of intravenous melphalan for metastatic colorectal carcinoma - A Southwest Oncology Group study",

abstract = "Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting dose of 40 mg/m2 was reduced to 30 mg/m2 after severe myelotoxicity was encountered in the first five patients. Toxicity was primarily myeloid and was moderate to severe in most patients with one treatment related death. There were two complete and one partial response among 43 patients. Melphalan at 30 mg/m2 has little activity among patients with metastatic colorectal carcinoma.",

keywords = "colon cancer, melphalan",

author = "Knight, {William A.} and Phyllis Goodman and Taylor, {Sarah A.} and Macdonald, {John S.} and Coltman, {Charles A.} and Constanzi, {John J.} and Baker, {Laurence H.}",

year = "1990",

month = mar,

doi = "10.1007/BF00171991",

language = "English (US)",

volume = "8",

pages = "S87--S89",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1 Supplement",

}

TY - JOUR

T1 - Phase II trial of intravenous melphalan for metastatic colorectal carcinoma - A Southwest Oncology Group study

AU - Knight, William A.

AU - Goodman, Phyllis

AU - Taylor, Sarah A.

AU - Macdonald, John S.

AU - Coltman, Charles A.

AU - Constanzi, John J.

AU - Baker, Laurence H.

PY - 1990/3

Y1 - 1990/3

N2 - Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting dose of 40 mg/m2 was reduced to 30 mg/m2 after severe myelotoxicity was encountered in the first five patients. Toxicity was primarily myeloid and was moderate to severe in most patients with one treatment related death. There were two complete and one partial response among 43 patients. Melphalan at 30 mg/m2 has little activity among patients with metastatic colorectal carcinoma.

AB - Based on the high response rates seen among patients with colon cancer receiving high dose Melphalan with autologous marrow infusion, the Southwest Oncology Group conducted a Phase II trial of the compound at a conventional dose. The initial starting dose of 40 mg/m2 was reduced to 30 mg/m2 after severe myelotoxicity was encountered in the first five patients. Toxicity was primarily myeloid and was moderate to severe in most patients with one treatment related death. There were two complete and one partial response among 43 patients. Melphalan at 30 mg/m2 has little activity among patients with metastatic colorectal carcinoma.

KW - colon cancer

KW - melphalan

UR - http://www.scopus.com/inward/record.url?scp=0025360006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025360006&partnerID=8YFLogxK

U2 - 10.1007/BF00171991

DO - 10.1007/BF00171991

M3 - Article

C2 - 2380020

AN - SCOPUS:0025360006

VL - 8

SP - S87-S89

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1 Supplement

ER -

Phase II trial of intravenous melphalan for metastatic colorectal carcinoma - A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this